Literature DB >> 8880060

Inhibition by a putative antipsychotic quinolinone derivative (OPC-14597) of dopaminergic neurons in the ventral tegmental area.

T Momiyama1, T Amano, N Todo, M Sasa.   

Abstract

The effects of the newly synthesized quinolinone derivative, OPC-14597 (7-{4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butyloxy}-3, 4-dihydro-2(1 H)-quinolinone), on dopaminergic neuronal activity in the ventral tegmental area were examined using both in vivo microiontophoretic methods in chloral hydrate-anesthetized rats and the tight-seal whole-cell patch-clamp technique in thin-slice preparations of the rat brain. Neurons in the ventral tegmental area were classified as type I or type II according to their responses to antidromic stimulation of the nucleus accumbens, probably corresponding to dopaminergic and non-dopaminergic neurons, respectively. Antidromic spikes elicited by nucleus accumbens stimulation were inhibited by microiontophoretic application of dopamine and OPC-14597 in type I, but not in type II neurons. Although the OPC-14597-induced inhibition was antagonized by simultaneous application of domperidone (5-chloro-1-[1-[3-(2,3-dihydro-2-oxo-1 H-benzimidazo-1-yl)-propy]-4-piperidinyl]-1,3-dihydro-2H- benzimidazol-2-one; dopamine D2 receptor antagonist), SCH 23390 (R(+)-7-chloro-8-hydroxy-3-methyl-1-phenyl-2,3,4, 5-tetrahydro-1 H-3-benzazepine hydrochloride; dopamine D1 receptor antagonist) had no such effect. Spontaneous firing of type I neurons was also inhibited by iontophoretically applied OPC-14597 and dopamine, whereas that of type II neurons was unaffected. The inhibitory effect of OPC-14597 on the spontaneous firing of type I neurons was antagonized by domperidone, but not by SCH 23390. In a whole-cell patch-clamp study using a thin-slice preparation of the rat brain, bath application of OPC-14597 induced hyperpolarization accompanied by inhibition of spontaneously occurring action potentials in the large neurons (> 20 microns in diameter) in a concentration-dependent manner. These results suggest that OPC-14597 acts on dopaminergic neurons in the ventral tegmental area as a dopamine D2 receptor agonist to inhibit neuronal activities, probably by increasing membrane potassium conductance.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8880060     DOI: 10.1016/0014-2999(96)00350-0

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  10 in total

1.  Activation of human D3 dopamine receptor inhibits P/Q-type calcium channels and secretory activity in AtT-20 cells.

Authors:  E V Kuzhikandathil; G S Oxford
Journal:  J Neurosci       Date:  1999-03-01       Impact factor: 6.167

2.  State-dependent effects of the D2 partial agonist aripiprazole on dopamine neuron activity in the MAM neurodevelopmental model of schizophrenia.

Authors:  Susan F Sonnenschein; Kathryn M Gill; Anthony A Grace
Journal:  Neuropsychopharmacology       Date:  2018-09-18       Impact factor: 7.853

Review 3.  Aripiprazole: a review of its use in the management of schizophrenia in adults.

Authors:  Jamie D Croxtall
Journal:  CNS Drugs       Date:  2012-02-01       Impact factor: 5.749

4.  In vivo actions of aripiprazole on serotonergic and dopaminergic systems in rodent brain.

Authors:  A Bortolozzi; L Díaz-Mataix; M Toth; P Celada; F Artigas
Journal:  Psychopharmacology (Berl)       Date:  2007-01-30       Impact factor: 4.530

5.  Altered neurotransmission in the mesolimbic reward system of Girk mice.

Authors:  Devinder Arora; Desirae M Haluk; Saïd Kourrich; Marco Pravetoni; Laura Fernández-Alacid; Joel C Nicolau; Rafael Luján; Kevin Wickman
Journal:  J Neurochem       Date:  2010-06-16       Impact factor: 5.372

6.  Effects of novel antipsychotics, amisulpiride and aripiprazole, on maternal behavior in rats.

Authors:  Ming Li; Radek Budin; Alison S Fleming; Shitij Kapur
Journal:  Psychopharmacology (Berl)       Date:  2005-10-12       Impact factor: 4.530

7.  Repeated aripiprazole administration attenuates cocaine seeking in a rat model of relapse.

Authors:  Matthew W Feltenstein; Phong H Do; Ronald E See
Journal:  Psychopharmacology (Berl)       Date:  2009-09-25       Impact factor: 4.530

Review 8.  Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder.

Authors:  Tracy Swainston Harrison; Caroline M Perry
Journal:  Drugs       Date:  2004       Impact factor: 9.546

9.  Antidepressant response to aripiprazole augmentation associated with enhanced FDOPA utilization in striatum: a preliminary PET study.

Authors:  Charles R Conway; John T Chibnall; Paul Cumming; Mark A Mintun; Marie Anne I Gebara; Dana C Perantie; Joseph L Price; Martha E Cornell; Jonathan E McConathy; Sunil Gangwani; Yvette I Sheline
Journal:  Psychiatry Res       Date:  2014-01-14       Impact factor: 3.222

10.  Aripiprazole (OPC-14597) fully substitutes for the 5-HT1A receptor agonist LY293284 in the drug discrimination assay in rats.

Authors:  Danuta Marona-Lewicka; David E Nichols
Journal:  Psychopharmacology (Berl)       Date:  2003-11-28       Impact factor: 4.530

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.